Abstract Details
|
Rohit Dhall, MD, FAAN
(University of Arkansas for Medical Sciences)
PRESENTER |
Dr. Dhall has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Best Doctors Inc. Dr. Dhall has stock in Verve Therapeutics Inc. Dr. Dhall has stock in Roche Holding Limited. Dr. Dhall has stock in Enliven Therapeutics Inc. The institution of Dr. Dhall has received research support from Amneal. The institution of Dr. Dhall has received research support from Neuroderm. The institution of Dr. Dhall has received research support from Cerevel Therapeutics. The institution of Dr. Dhall has received research support from Neurocrine. The institution of Dr. Dhall has received research support from Neuraly. The institution of Dr. Dhall has received research support from SPARC. The institution of Dr. Dhall has received research support from Pharma2B. The institution of Dr. Dhall has received research support from Alexion. The institution of Dr. Dhall has received research support from Parkinsons Foundation. The institution of Dr. Dhall has received research support from UCB Pharma. The institution of Dr. Dhall has received research support from Inhibikase Therapeutics. The institution of Dr. Dhall has received research support from Amylyx Pharma. |
| Ramon Gil, MD (Parkinson'S Disease Treatment Center of SW FL) | No disclosure on file |
| No disclosure on file | |
| Robert P. Rubens, MD, MBA, FAAN, FAAN (NeuroDevMA Consulting, Inc.) | Dr. Rubens has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Dr. Rubens has received stock or an ownership interest from Takeda Pharmaceuticals. |
| Suneel K. Gupta, PhD | No disclosure on file |